Review



human npscs with mg132  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    MedChemExpress human npscs with mg132
    Fig. 5 RBX1-mediated ubiquitination modulates NCOA4 expression. A The relative mRNA levels of NCOA4 in acidic and control groups. B, C prediction of E3 ligases targeting NCOA4 as substrate using the online tool UbiBrowser. D, E Stable RBX1-deficient and MDM2-deficient NPSCs were subjected to Western blot analysis to validate the efficiency. F, G Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1-siRNA and Control-siRNA. The relative band densities were quantified. H, I Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MDM2-siRNA and Control-siRNA. The relative band densities were quantified. J, K Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1 overexpression under acidic condition. The relative band densities were quantified. L Co-IP analysis of the binding between NCOA4 and RBX1. M NPSCs were treated with acidic condition for 24 h and the Co-IP analysis of the binding between NCOA4 and RBX1 was shown. N, O Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with <t>MG132,</t> the proteasome inhibitor. The relative band densities were quantified. A P-value less than 0.05 was deemed to be statistically significant. (*P < 0.05; **P < 0.01; ns, not significant)
    Human Npscs With Mg132, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 2425 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+npscs+with+mg132/pm40335979-145-2-6?v=MedChemExpress
    Average 99 stars, based on 2425 article reviews
    human npscs with mg132 - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "RBX1 mitigates ferroptosis by inhibiting NCOA4-mediated ferritinophagy and contributes to the attenuation of intervertebral disc degeneration."

    Article Title: RBX1 mitigates ferroptosis by inhibiting NCOA4-mediated ferritinophagy and contributes to the attenuation of intervertebral disc degeneration.

    Journal: Journal of translational medicine

    doi: 10.1186/s12967-025-06412-7

    Fig. 5 RBX1-mediated ubiquitination modulates NCOA4 expression. A The relative mRNA levels of NCOA4 in acidic and control groups. B, C prediction of E3 ligases targeting NCOA4 as substrate using the online tool UbiBrowser. D, E Stable RBX1-deficient and MDM2-deficient NPSCs were subjected to Western blot analysis to validate the efficiency. F, G Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1-siRNA and Control-siRNA. The relative band densities were quantified. H, I Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MDM2-siRNA and Control-siRNA. The relative band densities were quantified. J, K Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1 overexpression under acidic condition. The relative band densities were quantified. L Co-IP analysis of the binding between NCOA4 and RBX1. M NPSCs were treated with acidic condition for 24 h and the Co-IP analysis of the binding between NCOA4 and RBX1 was shown. N, O Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MG132, the proteasome inhibitor. The relative band densities were quantified. A P-value less than 0.05 was deemed to be statistically significant. (*P < 0.05; **P < 0.01; ns, not significant)
    Figure Legend Snippet: Fig. 5 RBX1-mediated ubiquitination modulates NCOA4 expression. A The relative mRNA levels of NCOA4 in acidic and control groups. B, C prediction of E3 ligases targeting NCOA4 as substrate using the online tool UbiBrowser. D, E Stable RBX1-deficient and MDM2-deficient NPSCs were subjected to Western blot analysis to validate the efficiency. F, G Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1-siRNA and Control-siRNA. The relative band densities were quantified. H, I Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MDM2-siRNA and Control-siRNA. The relative band densities were quantified. J, K Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1 overexpression under acidic condition. The relative band densities were quantified. L Co-IP analysis of the binding between NCOA4 and RBX1. M NPSCs were treated with acidic condition for 24 h and the Co-IP analysis of the binding between NCOA4 and RBX1 was shown. N, O Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MG132, the proteasome inhibitor. The relative band densities were quantified. A P-value less than 0.05 was deemed to be statistically significant. (*P < 0.05; **P < 0.01; ns, not significant)

    Techniques Used: Ubiquitin Proteomics, Expressing, Control, Western Blot, Over Expression, Co-Immunoprecipitation Assay, Binding Assay



    Similar Products

    human npscs with mg132  (MedChemExpress)
    99
    MedChemExpress human npscs with mg132
    Fig. 5 RBX1-mediated ubiquitination modulates NCOA4 expression. A The relative mRNA levels of NCOA4 in acidic and control groups. B, C prediction of E3 ligases targeting NCOA4 as substrate using the online tool UbiBrowser. D, E Stable RBX1-deficient and MDM2-deficient NPSCs were subjected to Western blot analysis to validate the efficiency. F, G Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1-siRNA and Control-siRNA. The relative band densities were quantified. H, I Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MDM2-siRNA and Control-siRNA. The relative band densities were quantified. J, K Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1 overexpression under acidic condition. The relative band densities were quantified. L Co-IP analysis of the binding between NCOA4 and RBX1. M NPSCs were treated with acidic condition for 24 h and the Co-IP analysis of the binding between NCOA4 and RBX1 was shown. N, O Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with <t>MG132,</t> the proteasome inhibitor. The relative band densities were quantified. A P-value less than 0.05 was deemed to be statistically significant. (*P < 0.05; **P < 0.01; ns, not significant)
    Human Npscs With Mg132, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+npscs+with+mg132/pm40335979-145-2-6?v=MedChemExpress
    Average 99 stars, based on 1 article reviews
    human npscs with mg132 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 5 RBX1-mediated ubiquitination modulates NCOA4 expression. A The relative mRNA levels of NCOA4 in acidic and control groups. B, C prediction of E3 ligases targeting NCOA4 as substrate using the online tool UbiBrowser. D, E Stable RBX1-deficient and MDM2-deficient NPSCs were subjected to Western blot analysis to validate the efficiency. F, G Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1-siRNA and Control-siRNA. The relative band densities were quantified. H, I Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MDM2-siRNA and Control-siRNA. The relative band densities were quantified. J, K Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1 overexpression under acidic condition. The relative band densities were quantified. L Co-IP analysis of the binding between NCOA4 and RBX1. M NPSCs were treated with acidic condition for 24 h and the Co-IP analysis of the binding between NCOA4 and RBX1 was shown. N, O Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MG132, the proteasome inhibitor. The relative band densities were quantified. A P-value less than 0.05 was deemed to be statistically significant. (*P < 0.05; **P < 0.01; ns, not significant)

    Journal: Journal of translational medicine

    Article Title: RBX1 mitigates ferroptosis by inhibiting NCOA4-mediated ferritinophagy and contributes to the attenuation of intervertebral disc degeneration.

    doi: 10.1186/s12967-025-06412-7

    Figure Lengend Snippet: Fig. 5 RBX1-mediated ubiquitination modulates NCOA4 expression. A The relative mRNA levels of NCOA4 in acidic and control groups. B, C prediction of E3 ligases targeting NCOA4 as substrate using the online tool UbiBrowser. D, E Stable RBX1-deficient and MDM2-deficient NPSCs were subjected to Western blot analysis to validate the efficiency. F, G Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1-siRNA and Control-siRNA. The relative band densities were quantified. H, I Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MDM2-siRNA and Control-siRNA. The relative band densities were quantified. J, K Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with RBX1 overexpression under acidic condition. The relative band densities were quantified. L Co-IP analysis of the binding between NCOA4 and RBX1. M NPSCs were treated with acidic condition for 24 h and the Co-IP analysis of the binding between NCOA4 and RBX1 was shown. N, O Western blot analysis showing the protein expression level of NCOA4 after NPSCs treated with MG132, the proteasome inhibitor. The relative band densities were quantified. A P-value less than 0.05 was deemed to be statistically significant. (*P < 0.05; **P < 0.01; ns, not significant)

    Article Snippet: We treated human NPSCs with MG132 (MCE, HY-13259) to suppress proteasome-mediated protein degradation and investigate whether RBX1 destabilizes NCOA4 protein.

    Techniques: Ubiquitin Proteomics, Expressing, Control, Western Blot, Over Expression, Co-Immunoprecipitation Assay, Binding Assay